NextCell Pharma: Interim data around the corner - Redeye
Redeye comments on NextCell Pharma ahead of the upcoming interim data from ProTrans-Young, set to be presented in connection with the IDF World Diabetes Congress in Bangkok next week—a potential near-term catalyst for the share.
ANNONS
Redeye comments on NextCell Pharma ahead of the upcoming interim data from ProTrans-Young, set to be presented in connection with the IDF World Diabetes Congress in Bangkok next week—a potential near-term catalyst for the share.